Key Highlights

  • Stryker (NYSE:SYK) lowered its 2026 outlook on October 29, 2026 to organic net sales growth of 6.5 percent to 7 percent from 8.3 percent to 9.3 percent, and adjusted EPS of USD 14.80 to USD 14.90 from USD 14.95 to USD 15.10.
  • Third quarter Organic Sales grew 7.7 percent to about USD 6.5 billion, under the USD 6.62 billion estimate, while adjusted EPS of USD 3.52 climbed 10.3 percent against a USD 3.55 estimate.
  • Hip sales slipped 1 percent to USD 453 million and knee sales edged up 1.1 percent to USD 635 million, while Ortho Tech rose 15.8 percent and endoscopy 13.9 percent.
  • Chief executive Kevin Lobo said the quarter fell short of expectations, and shares of Stryker (NYSE:SYK) dropped roughly 5 percent on October 30, 2026, according to published coverage.

A Miss and a Cut in the Same Release

Stryker (NYSE:SYK) published third quarter results on October 29, 2026, and coverage dated October 30 detailed the market reaction. Organic net sales growth of 7.7 percent produced Revenue of about USD 6.5 billion, below the USD 6.62 billion estimate. Adjusted EPS of USD 3.52 barely missed the USD 3.55 estimate. The bigger signal was guidance: organic growth for 2026 now sits at 6.5 percent to 7 percent, far below the 8.3 percent to 9.3 percent set in July, and adjusted EPS of USD 14.80 to USD 14.90 falls under a consensus near USD 14.95. Net Earnings reportedly dropped 12.3 percent to USD 753 million, including a USD 293 million Goodwill impairment.

Where Growth Fell Short

The weak spot was joint replacement. Hip sales dipped 1 percent while knee sales rose 1.1 percent, whereas Johnson & Johnson (NYSE:JNJ) reported knee growth of 2.5 percent and hip growth of 3.2 percent in the same period, according to published coverage. Lobo said it is now clear there is a market slowdown and that Stryker has not been winning at its historical rate. Coverage tied the shortfall to a cyber incident, a July software system rollout and slow uptake of new products. Other lines held up: Ortho Tech rose 15.8 percent and endoscopy 13.9 percent. Stryker (NYSE:SYK) therefore has strong areas, but its largest Franchise is lagging.

Valuation, Risks and What to Watch

Before the report, the stock traded at about 19 times forward earnings against a five year average near 26 times, and about 17 times after the decline, per published coverage. A lower multiple does not mean cheap, because the guidance cut shows estimates can fall. The risks are further share loss in hips and knees, execution on the system rollout and the pace of new product adoption. Investors will watch whether the market slowdown persists and whether Stryker (NYSE:SYK) regains its historical growth rate. A published figure of a 10 percent drop for the shares was not confirmed. This is not a forecast.

Where Things Stand

The company is Stryker (NYSE:SYK), and its guidance cut is driven by joint replacement, where hip sales fell 1 percent and management admitted share losses. Overall sales still grew 7.7 percent organically, and several product lines expanded in double digits. The weight of evidence points to a growth reset rather than a collapse, but it breaks a long record of beats. The next catalysts are fourth quarter results and evidence that orthopaedics growth recovers toward the 6.5 percent to 7 percent full-year range.